Anidulafungin

Anidulafungin is a semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used to treat invasive candidiasis. It is an azamacrocycle, a heterodetic cyclic peptide, a semisynthetic derivative, an echinocandin and an antibiotic antifungal drug. Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin. Its therapeutic use is listed as anti-infectives and antifungals. The directory classifies it as a commercial API with a peptide source/manufacturing origin. Other names for this substance include Ecalta, V-Echinocandin and Eraxis. Its PubChem CID is 166548.

CAS No 166663-25-8
Molecular Formula C58H73N7O17
Molecular Weight 1140.24 g/mol
Synonyms N-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide

Zoho Contact Form

"*" indicates required fields

I am a*
This field is for validation purposes and should be left unchanged.

Frequently Asked Questions